+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Hemoglobinopathies Market Size, Share & Trends Analysis Report by Type (Thalassemia, Sickle Cell Disease), Diagnosis (Thalassemia, Sickle Cell Disease), Therapy, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 80 Pages
  • June 2024
  • Region: United States
  • Grand View Research
  • ID: 5982990
Description Jump to:
The U.S. hemoglobinopathies market size is anticipated to reach USD 6.85 billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030. The rising prevalence of hemoglobinopathies, such as sickle cell disease and thalassemia, is a significant market driver. Advances in diagnostic techniques, such as genetic testing and prenatal screening, have improved the early detection of hemoglobinopathies. In addition, ongoing research into novel treatment options, including gene therapy and gene editing technologies like CRISPR-Cas9, holds promise for more effective therapies in the future.

The growing government initiatives to raise awareness about hemoglobinopathies and improved access to care for affected individuals play a crucial role in driving the market. Funding support for research and development efforts also accelerates innovation in this field.

Collaboration between pharmaceutical companies, research institutions, and healthcare providers fosters the development of new therapies and enhances patient care. Partnerships that leverage companies’ strengths can accelerate drug development and improve treatment outcomes.

U.S. Hemoglobinopathies Market Report Highlights

  • Sickle cell disease type dominated the type segment with 60.1% share in 2023 and is expected to grow at fastest CAGR over the forecast period. The growth is attributed to the increasing Initiatives of Biopharmaceutical Companies and Nonprofit Organizations Driving Improved Access to Sickle Cell Disease (SCD) Treatment.
  • The sickle cell disease diagnosis segment held the largest market in 2023. Advancements including genetic testing methods such as next-generation sequencing and molecular diagnostics are propelling the segment growth.
  • The sickle cell disease therapy segment held the largest market in 2023. The growing approval of innovative therapies, such as gene therapies and targeted treatments, designed to modify genetic abnormalities are propelling market growth.
  • In April 2022, Sangamo Therapeutics, a genomic medicines company, announced the transition of its SAR445136 sickle cell disease program from Sanofi to Sangamo. This transition marks a significant step in the development of a gene-edited therapy for sickle cell disease.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Diagnosis
1.2.3. Therapy
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Diagnosis outlook
2.2.3. Therapy outlook
2.3. Competitive Insights
Chapter 3. U.S. Hemoglobinopathies Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Hemoglobinopathies Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Hemoglobinopathies Market: Type Estimates & Trend Analysis
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Hemoglobinopathies Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Thalassemia
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Sickle cell disease
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Other Hb variants
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Hemoglobinopathies Market: Diagnosis Estimates & Trend Analysis
5.1. Diagnosis Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Hemoglobinopathies Market by Diagnosis Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Thalassemia
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2. Alpha
5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.2. Blood test
5.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.3. Genetic test
5.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.4. Prenatal genetic test
5.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.5. Pre-implantation genetic test
5.4.1.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.6. Electrophoresis
5.4.1.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.2.7. Others
5.4.1.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3. Beta
5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.2. Blood test
5.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.3. Genetic test
5.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.4. Prenatal genetic test
5.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.5. Pre-implantation genetic test
5.4.1.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.6. Electrophoresis
5.4.1.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.1.3.7. Others
5.4.1.3.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Sickle cell disease
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.2. Blood test
5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.3. Genetic test
5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.4. Prenatal genetic test
5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.5. Electrophoresis
5.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2.6. Others
5.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Hb variants
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.2. Blood test
5.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.3. Genetic test
5.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.4. Prenatal genetic test
5.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.5. Electrophoresis
5.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3.6. Others
5.4.3.7. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Hemoglobinopathies Market: Therapy Estimates & Trend Analysis
6.1. Therapy Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Hemoglobinopathies Market by Therapy Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Thalassemia
6.4.1.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.2. Alpha
6.4.1.2.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.2.2. Blood transfusion
6.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.2.2. Iron chelation therapy
6.4.1.2.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.3. Bone marrow transplant
6.4.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2.4. Others
6.4.1.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3. Beta
6.4.1.3.1. Market estimates and forecasts 2018 to 2030, (USD million)
6.4.1.3.2. Blood transfusion
6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.2.2. Iron chelation therapy
6.4.1.3.2.3. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.3. Bone marrow transplant
6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.4. Others
6.4.1.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Sickle Cell Disease
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.2. Blood transfusion
6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.3. Hydroxyurea
6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.4. Bone marrow transplant
6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.5. Others
6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. (Hb) Variants
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.2. Blood transfusion
6.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.3. Hydroxyurea
6.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.4. Bone marrow transplant
6.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3.5. Others
6.4.3.6. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company heat map analysis, 2023
7.4. Company Profiles
7.4.1. Sangamo Therapeutics, Inc.
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. Global Blood Therapeutics, Inc.
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. bluebird bio, Inc.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Emmaus Life Sciences Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. Pfizer, Inc.
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Novartis AG
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Prolong Pharmaceuticals, LLC
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Bioverativ Inc.
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Celgene Corp.
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S. hemoglobinopathies market, by type, 2018-2030 (USD Million)
Table 3 U.S. hemoglobinopathies market, by diagnosis, 2018-2030 (USD Million)
Table 4 U.S. hemoglobinopathies market, by therapy, 2018-2030 (USD Million)
Table 5 U.S. thalassemia market, by diagnosis, 2018-2030 (USD Million)
Table 6 U.S. hemoglobinopathies market, by therapy, 2018-2030 (USD Million)
Table 7 U.S. alpha thalassemia market, by diagnosis, 2018-2030 (USD Million)
Table 8 U.S. beta thalassemia market, by diagnosis, 2018-2030 (USD Million)
Table 9 U.S. thalassemia market, by therapy, 2018-2030 (USD Million)
Table 10 U.S. alpha thalassemia market, by therapy, 2018-2030 (USD Million)
Table 11 U.S. beta thalassemia market, by therapy, 2018-2030 (USD Million)
Table 12 U.S. sickle cell disease market, by diagnosis, 2018-2030 (USD Million)
Table 13 U.S. sickle cell disease market, by therapy, 2018-2030 (USD Million)
Table 14 U.S. Hb Variants market, by diagnosis, 2018-2030 (USD Million)
Table 15 U.S. hemoglobinopathies market, by region, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value-chain-based sizing & forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market formulation & validation
Figure 8 U.S. hemoglobinopathies market: market outlook
Figure 9 U.S. hemoglobinopathies competitive insights
Figure 10 Parent market outlook
Figure 11 Related/ancillary market outlook
Figure 12 Penetration and growth prospect mapping
Figure 13 Industry value chain analysis
Figure 14 U.S. hemoglobinopathies market driver impact
Figure 15 U.S. hemoglobinopathies market restraint impact
Figure 16 U.S. hemoglobinopathies market strategic initiatives analysis
Figure 17 U.S. hemoglobinopathies market: Type movement analysis
Figure 18 U.S. hemoglobinopathies market: Type outlook and key takeaways
Figure 19 Thalassemia market estimates and forecasts, 2018-2030 (USD Million)
Figure 20 Sickle cell diseases market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 Other Hb variants estimates and forecasts, 2018-2030 (USD Million)
Figure 22 U.S. hemoglobinopathies Market: Diagnosis movement Analysis
Figure 23 U.S. hemoglobinopathies market: Diagnosis outlook and key takeaways
Figure 24 Thalassemia market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 Alpha market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Blood test market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 Prenatal genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 29 Pre-implantation genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 Electrophoresis market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Other market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Beta market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Blood test market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Prenatal genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Pre-implantation genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Electrophoresis market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 Other market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 Sickle cell disease market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Blood test market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 Prenatal genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Electrophoresis market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 (Hb) variants market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Blood test market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Prenatal genetic test market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Electrophoresis market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 U.S. hemoglobinopathies Market: Therapy movement Analysis
Figure 52 U.S. hemoglobinopathies market: Therapy outlook and key takeaways
Figure 53 Thalassemia market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Alpha market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Blood transfusion market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 Iron chelation therapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Bone marrow transplant test market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 59 Beta market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 Blood transfusion market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Iron chelation therapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 62 Bone marrow transplant test market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Sickle cell disease market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Blood transfusion market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Hydroxyurea market estimates and forecasts, 2018-2030 (USD Million)
Figure 67 Bone marrow transplant test market estimates and forecasts, 2018-2030 (USD Million)
Figure 68 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 69 (Hb) variants market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Blood transfusion market estimates and forecasts, 2018-2030 (USD Million)
Figure 71 Hydroxyurea market estimates and forecasts, 2018-2030 (USD Million)
Figure 72 Bone marrow transplant test market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 74 U.S. hemoglobinopathies market: regional movement analysis
Figure 75 U.S. hemoglobinopathies market: regional outlook and key takeaways
Figure 76 West market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Midwest market estimates and forecasts, 2018-2030 (USD Million)
Figure 78 Northeast market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Southwest market estimates and forecasts, 2018-2030 (USD Million)
Figure 80 Southeast market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • Sangamo Therapeutics, Inc.
  • Global Blood Therapeutics, Inc.
  • bluebird bio, Inc.
  • Emmaus Life Sciences Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Prolong Pharmaceuticals, LLC
  • Bioverativ Inc.
  • Celgene Corp.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages80
PublishedJune 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 3.09 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.85 Billion
Compound Annual Growth Rate12.5%
Regions CoveredUnited States
No. of Companies Mentioned9

Related Topics

Related Reports

Hemoglobinopathies Market by Indication, Treatment, Diagnosis, End-User - Global Forecast 2025-2030 - Product Image

Hemoglobinopathies Market by Indication, Treatment, Diagnosis, End-User - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Hemoglobinopathies - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Hemoglobinopathies - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2024-2032 - Product Image

Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Hemoglobinopathies - Global Strategic Business Report - Product Image

Hemoglobinopathies - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
North America Hemoglobinopathies Market Report and Forecast 2024-2032 - Product Image

North America Hemoglobinopathies Market Report and Forecast 2024-2032

  • Report
  • 120 Pages
  • North America
From

About the Hemoglobinopathies Drug Market

Hemoglobinopathies are a group of inherited blood disorders caused by abnormal hemoglobin production. Hemoglobin is the protein in red blood cells that carries oxygen throughout the body. Hemoglobinopathies can cause anemia, fatigue, and other health problems. Treatment for hemoglobinopathies typically involves medications to increase red blood cell production, reduce symptoms, and prevent complications. The hemoglobinopathies drug market is a subset of the hematological drugs market. It includes drugs used to treat hemoglobinopathies, such as hydroxyurea, decitabine, and l-glutamine. These drugs are used to reduce the severity of symptoms, increase red blood cell production, and prevent complications. Companies in the hemoglobinopathies drug market include Novartis, Pfizer, GlaxoSmithKline, Merck, and Sanofi. These companies produce and market drugs used to treat hemoglobinopathies. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.